Special Issue

Biomarkers in Diagnosis and Management of Hepatocellular Carcinoma

Message from the Guest Editors

Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer-related deaths, with more than 50% of patients dying within five years of diagnosis. A lack of effective early detection tools, the limited treatment options for advanced stages, and the high frequency of HCC recurrence contribute to this poor prognosis. Despite the implementation of HCC screening programs for well-known at-risk populations, the majority of HCCs are diagnosed at late stages. indicating the need for more sensitive early biomarkers and patient-friendly (patient-accessible?) diagnostic tests for HCC screening. This Special Issue will cover recent advances in biomarkers discovery and development for HCC screening, diagnosis, stratification, management, and drug development. The scope of the issue includes both technology and biomarkers.

Guest Editors

Prof. Ying-Hsiu Su

Department of Translational Medical Science, The Baruch S. Blumberg Institute, Doylestown, PA, USA

Dr. Amy K. Kim

Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA

Deadline for manuscript submissions

closed (20 December 2022)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/85309

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

